Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide
Abstract Lenalidomide is an immunomodulatory drug that is administered commonly in patients with relapsed or refractory multiple myeloma (RRMM). Eosinophils have immunological functions, for instance, in allergic diseases and asthma. The purpose of this study was to investigate the clinical signific...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2828 |
| _version_ | 1827070419006390272 |
|---|---|
| author | Kazuhito Suzuki Kaichi Nishiwaki Tadahiro Gunji Mitsuji Katori Hidekazu Masuoka Shingo Yano |
| author_facet | Kazuhito Suzuki Kaichi Nishiwaki Tadahiro Gunji Mitsuji Katori Hidekazu Masuoka Shingo Yano |
| author_sort | Kazuhito Suzuki |
| collection | DOAJ |
| description | Abstract Lenalidomide is an immunomodulatory drug that is administered commonly in patients with relapsed or refractory multiple myeloma (RRMM). Eosinophils have immunological functions, for instance, in allergic diseases and asthma. The purpose of this study was to investigate the clinical significance of elevated eosinophil levels in patients with RRMM treated with lenalidomide. A total of 59 patients were included. Elevated eosinophil level was defined as an increase in the eosinophil count of ≥250/µL from the eosinophil count on day 1 during the first cycle. The percentage of patients with elevated eosinophil levels was 22.0%. The overall response ratio in the elevated eosinophil group and nonelevated eosinophil group was 84.6% and 63.0% (P = .189), respectively. The median time to next treatment (TTNT) in the elevated eosinophil group was significantly longer than that in the nonelevated group (40.3 months vs 8.4 months; P = .017). Additionally, TTNT in the elevated eosinophil group with partial response (PR) or better was significantly longer than that in the nonelevated eosinophil group with PR or better (40.3 months vs 11.9 months; P = .021). We concluded that elevated eosinophil levels were frequently observed and might predict a longer TTNT in patients with RRMM treated with lenalidomide. |
| first_indexed | 2024-03-08T04:03:29Z |
| format | Article |
| id | doaj.art-49ae5377ef4c466aa404f2a9596791a0 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2025-03-20T00:22:12Z |
| publishDate | 2020-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-49ae5377ef4c466aa404f2a9596791a02024-10-10T11:30:42ZengWileyCancer Medicine2045-76342020-03-01951694170210.1002/cam4.2828Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomideKazuhito Suzuki0Kaichi Nishiwaki1Tadahiro Gunji2Mitsuji Katori3Hidekazu Masuoka4Shingo Yano5Division of Clinical Oncology and Hematology Department of Internal Medicine The Jikei University School of Medicine Tokyo JapanDivision of Clinical Oncology and Hematology Department of Internal Medicine The Jikei University School of Medicine Tokyo JapanDivision of Clinical Oncology and Hematology Department of Internal Medicine The Jikei University School of Medicine Tokyo JapanDivision of Clinical Oncology and Hematology Department of Internal Medicine The Jikei University School of Medicine Tokyo JapanDivision of Clinical Oncology and Hematology Department of Internal Medicine The Jikei University School of Medicine Tokyo JapanDivision of Clinical Oncology and Hematology Department of Internal Medicine The Jikei University School of Medicine Tokyo JapanAbstract Lenalidomide is an immunomodulatory drug that is administered commonly in patients with relapsed or refractory multiple myeloma (RRMM). Eosinophils have immunological functions, for instance, in allergic diseases and asthma. The purpose of this study was to investigate the clinical significance of elevated eosinophil levels in patients with RRMM treated with lenalidomide. A total of 59 patients were included. Elevated eosinophil level was defined as an increase in the eosinophil count of ≥250/µL from the eosinophil count on day 1 during the first cycle. The percentage of patients with elevated eosinophil levels was 22.0%. The overall response ratio in the elevated eosinophil group and nonelevated eosinophil group was 84.6% and 63.0% (P = .189), respectively. The median time to next treatment (TTNT) in the elevated eosinophil group was significantly longer than that in the nonelevated group (40.3 months vs 8.4 months; P = .017). Additionally, TTNT in the elevated eosinophil group with partial response (PR) or better was significantly longer than that in the nonelevated eosinophil group with PR or better (40.3 months vs 11.9 months; P = .021). We concluded that elevated eosinophil levels were frequently observed and might predict a longer TTNT in patients with RRMM treated with lenalidomide.https://doi.org/10.1002/cam4.2828chemotherapyhematological cancerimmunology |
| spellingShingle | Kazuhito Suzuki Kaichi Nishiwaki Tadahiro Gunji Mitsuji Katori Hidekazu Masuoka Shingo Yano Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide Cancer Medicine chemotherapy hematological cancer immunology |
| title | Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide |
| title_full | Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide |
| title_fullStr | Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide |
| title_full_unstemmed | Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide |
| title_short | Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide |
| title_sort | elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide |
| topic | chemotherapy hematological cancer immunology |
| url | https://doi.org/10.1002/cam4.2828 |
| work_keys_str_mv | AT kazuhitosuzuki elevatedeosinophillevelpredictedlongtimetonexttreatmentinrelapsedorrefractorymyelomapatientstreatedwithlenalidomide AT kaichinishiwaki elevatedeosinophillevelpredictedlongtimetonexttreatmentinrelapsedorrefractorymyelomapatientstreatedwithlenalidomide AT tadahirogunji elevatedeosinophillevelpredictedlongtimetonexttreatmentinrelapsedorrefractorymyelomapatientstreatedwithlenalidomide AT mitsujikatori elevatedeosinophillevelpredictedlongtimetonexttreatmentinrelapsedorrefractorymyelomapatientstreatedwithlenalidomide AT hidekazumasuoka elevatedeosinophillevelpredictedlongtimetonexttreatmentinrelapsedorrefractorymyelomapatientstreatedwithlenalidomide AT shingoyano elevatedeosinophillevelpredictedlongtimetonexttreatmentinrelapsedorrefractorymyelomapatientstreatedwithlenalidomide |